Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Sponsor: Centre Hospitalier Universitaire de Nīmes
Terminated
recruitment difficulties
A observational or N/A phase clinical study on Lupus Erythematosus, Cutaneous and Pemphigoid, Bullous, this trial is terminated or withdrawn. The trial is conducted by Centre Hospitalier Universitaire de Nīmes and has accumulated 11 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Study Description(click to expand)The secondary objectives of this study are:
To compare the following parameters between the 3 groups:
* plasmatic proteasome concentrations
* plasmatic proteasome proteolytic activity
To explore the potential relationships between:
* plasmatic proteasome concentrations
* plasmatic proteasome proteolytic activity
* plasmatic anti-proteasome auto-antibody concentrations
* measures of disease severity for dermatological auto-immune diseases
To characterize plasmatic anti-proteasome auto-antibodies in patients suffering from bullous pemphigoide and other dermatological auto-immune diseases (other bullous auto immune diseases: pemphigus, cutaneous lupus, ...).
To characterize the expression and the activity of proteasomes in skin samples, in plasma and in circulating mononuclear cells in patients with bullous pemphigoide.
The secondary objectives of this study are:
To compare the following parameters between the 3 groups:
* plasmatic proteasome concentrations * plasmatic proteasome proteolytic activity
To explore the potential relationships between:
* plasmatic proteasome concentrations * plasmatic proteasome proteolytic activity * plasmatic anti-proteasome auto-antibody concentrations * measures of disease severity for dermatological auto-immune diseases
To characterize plasmatic anti-proteasome auto-antibodies in patients suffering from bullous pemphigoide and other dermatological auto-immune diseases (other bullous auto immune diseases: pemphigus, cutaneous lupus, ...).
To characterize the expression and the activity of proteasomes in skin samples, in plasma and in circulating mononuclear cells in patients with bullous pemphigoide.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated
-
Jun 2018 — Nov 2020 [monthly]
Terminated
Status: Unknown Status → Terminated
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Status: Recruiting → Unknown Status · Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire de Nīmes
For direct contact, visit the study record on ClinicalTrials.gov .